SNAP-8

Source-reported examples · not treatment recommendations

Amount

0.0015%–0.005% active concentration in formulation examples

Frequency

Twice-daily application in the manufacturer example

Cycle / observation period

28 days in that example

Route / research model

Topical

This is a topical formulation entry, not an injection protocol. Manufacturer testing and multi-ingredient studies do not isolate the effect of SNAP-8.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Topical formulation: use the documented cosmetic vehicle and final concentration. An injectable diluent is not applicable to the cited topical example.

Available source strength: 10 mg. A body-weight-dependent animal exposure or topical batch concentration cannot be converted into a generic human vial count.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• SNAP-8 is associated with acetyl octapeptide-3 in the PubChem identity record. The selected human studies below tested multi-ingredient microneedle products containing that ingredient. Their findings should be attributed to the tested products, not treated as isolated proof of SNAP-8's contribution. ^[1]
• A study published online in 2019 evaluated a hyaluronic-acid microneedle product containing several additional ingredients, including acetyl octapeptide-3, another peptide, adenosine and seaweed extracts. The study followed healthy participants with aged skin for 12 weeks and reported improvements in instrumental skin measurements, including wrinkles. ^[2]
• A 2024 study enrolled 24 healthy participants and compared a dissolving microneedle product containing hyaluronic acid, acetyl octapeptide-3, a vitamin-C derivative and another active ingredient against a hyaluronic-acid microneedle comparator over 28 days. The paper reported better wrinkle outcomes for the active product. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 8 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. PubChem identity
2. Original study abstract
3. Original study
4. Journal of Drugs in Dermatology (2016). Draelos ZD, et al. Open-label topical multi-peptide serum and supporting regimen. Full article.Further reading · Listed in reference bibliography.
5. Journal of Analytical Science and Technology (2020). Ji Y, et al. LC-MS/MS method for SNAP-8 in a biodegradable microneedle patch and analytical-standard stability observations. Full article.Further reading · Listed in reference bibliography.
6. U.S. FDA Global Substance Registration System. Validated identity and amino-acid sequence for acetyl octapeptide-3. FDA substance record.Regulatory / product information · Listed in reference bibliography.
7. U.S. Food and Drug Administration. FDA authority over cosmetics and the distinction between cosmetic products and approved drugs. FDA cosmetics overview.Regulatory / product information · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.